Tranzactioneaza Inflarx (US.IFRX) - 0.8501 USD (%) Tranzactioneaza
Indici
Descriere companie
Inflarx NV, formerly Fireman BV, (https://www.inflarx.de/) is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.